Journal
NEUROPSYCHOPHARMACOLOGY
Volume 36, Issue 2, Pages 511-518Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/npp.2010.182
Keywords
dopamine 1 receptor; dopamine 2 receptor; dopamine transporter; electroconvulsive therapy; positron emission tomography; vesicular monoamine transporter 2
Categories
Funding
- Parkinson Society Canada
- Danish Medical Research Council
- CIHR [MOP 74746]
Ask authors/readers for more resources
Electroconvulsive therapy (ECT) is one of the most effective therapies for depression and has beneficial motor effects in parkinsonian patients. However, little is known about the mechanisms of therapeutic action of ECT for either condition. The aim of this work was to explore the impact of ECT on dopaminergic function in the striatum of non-human primates. Rhesus monkeys underwent a course of six ECT treatments under a human clinical protocol. Longitudinal effects on the dopaminergic nigrostriatal system were studied over 6 weeks using the in vivo capabilities of positron emission tomography (PET). PET scans were performed prior to the onset of ECT treatments and at 24-48 h, 8-10 days, and 6 weeks after the final ECT treatment. Early increases in dopamine transporter and vesicular monoamine transporter 2 binding returned to baseline levels by 6 weeks post-ECT. Transient increases in D1 receptor binding were also observed, whereas the binding potential to D2 receptors was unaltered. The increase in dopaminergic neurotransmission suggested by our results may account in part for the therapeutic effect of ECT in mood disorders and Parkinson's disease. Neuropsychopharmacology (2011) 36, 511-518; doi: 10.1038/npp.2010.182; published online 13 October 2010
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available